HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Puts Price Tag On False COVID-19 Claims

First Amendment No License For Health Care Providers To Make False Claims

Executive Summary

Until coronavirus public health emergency ends, FTC is authorized to order civil penalties of $43,792 per violation found in COVID-19-related advertising. Health care providers, meanwhile, advertising to treat COVID-19 might be unfamiliar with 

You may also be interested in...



False Treatment Claims Still A COVID-19 Symptom: FTC Files Complaint Against California Firm

FTC files complaint alleging Precision Patient Outcomes marketed a supplement as a treatment to mitigate the effects of COVID-19 after agency let the firm know it considered the claims false advertising.

Same Old Supplement Claim Violations Prompt US Regulators’ Action Under New COVID-19 Authority

FTC files complaint against Quickwork as first action under authority granted in the COVID-19 Consumer Protection Act. The enforcement came after the firm twice ingored warnings to discontinue claims its vitamin D and zinc supplements were equal to or more effective than current vaccines.

Symptoms Change But Savings OTC Drugs Deliver For US Health Care Spending Continue Growing

Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS150955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel